189 related articles for article (PubMed ID: 23807569)
21. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver.
Gaur SK; Friese JL; Sadow CA; Ayyagari R; Binkert CA; Schenker MP; Kulke M; Baum R
Cardiovasc Intervent Radiol; 2011 Jun; 34(3):566-72. PubMed ID: 21431978
[TBL] [Abstract][Full Text] [Related]
22. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.
Denecke T; Baur AD; Ihm C; Steffen IG; Tischer E; Arsenic R; Pascher A; Wiedenmann B; Pavel M
Eur J Radiol; 2013 Oct; 82(10):e550-5. PubMed ID: 23891296
[TBL] [Abstract][Full Text] [Related]
24. Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres.
Carle X; Gastaud L; Salleron J; Tardy MP; Caujolle JP; Thyss A; Thariat J; Chevallier P
Bull Cancer; 2020 Dec; 107(12):1274-1283. PubMed ID: 33183739
[TBL] [Abstract][Full Text] [Related]
25. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.
Vogl TJ; Gruber T; Naguib NN; Hammerstingl R; Nour-Eldin NE
AJR Am J Roentgenol; 2009 Oct; 193(4):941-7. PubMed ID: 19770314
[TBL] [Abstract][Full Text] [Related]
26. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
27. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study.
Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S
J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328
[TBL] [Abstract][Full Text] [Related]
28. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery.
Saxena A; Chua TC; Zhao J; Morris DL
J Surg Oncol; 2012 Mar; 105(4):342-50. PubMed ID: 22006355
[TBL] [Abstract][Full Text] [Related]
29. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
30. Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.
Onesti JK; Shirley LA; Saunders ND; Davidson GW; Dillhoff ME; Khabiri H; Guy GE; Dowell JD; Schmidt CR; Shah MH; Bloomston M
J Gastrointest Surg; 2016 Mar; 20(3):580-6. PubMed ID: 26489743
[TBL] [Abstract][Full Text] [Related]
31. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
Gupta S; Yao JC; Ahrar K; Wallace MJ; Morello FA; Madoff DC; Murthy R; Hicks ME; Ajani JA
Cancer J; 2003; 9(4):261-7. PubMed ID: 12967136
[TBL] [Abstract][Full Text] [Related]
32. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
33. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases.
Kamat PP; Gupta S; Ensor JE; Murthy R; Ahrar K; Madoff DC; Wallace MJ; Hicks ME
Cardiovasc Intervent Radiol; 2008; 31(2):299-307. PubMed ID: 17922160
[TBL] [Abstract][Full Text] [Related]
34. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
35. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
[TBL] [Abstract][Full Text] [Related]
36. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
[TBL] [Abstract][Full Text] [Related]
37. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
[TBL] [Abstract][Full Text] [Related]
38. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
39. Hepatic neuroendocrine metastases: does intervention alter outcomes?
Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
[TBL] [Abstract][Full Text] [Related]
40. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
